



iJRASET

International Journal For Research in
Applied Science and Engineering Technology



INTERNATIONAL JOURNAL FOR RESEARCH

IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY

Volume: 12 **Issue:** IX **Month of publication:** September 2024

DOI: <https://doi.org/10.22214/ijraset.2024.64136>

www.ijraset.com

Call: ☎ 08813907089

E-mail ID: ijraset@gmail.com

Analytical Method Development and Validation of RP-HPLC Method for Estimation of Venetoclax in Pharmaceutical Dosage Form

Shubham Rasal¹, Vijay Kumar Munipalli², Sayali Warde³, Smita Nayak⁴, Bhaskar Vaidhun⁵

^{1, 4, 5}Department of Quality Assurance, Gahlot Institute of Pharmacy, University of Mumbai, Sector-14, Koparkhairane, Navi Mumbai, Maharashtra, India-400709

^{2, 3}Analytical Research and Development, Central Drugs Testing Laboratory, Zonal FDA Bhavan, GMSD Compound, Bellasis Road, Mumbai Central, Mumbai, Maharashtra, India-400008

Abstract: A simple and new isocratic high-performance liquid chromatography (HPLC) method was developed for the quantitative determination of Venetoclax in its tablet dosage form. The chromatographic separation was achieved on Perkin C8 (15cm x 4.6mm id, 5 μ) column. The mobile phase selected was buffer (25 mm ammonium acetate) adjusted to pH 3.0 with orthophosphoric acid and acetonitrile in the ratio of (55:45) v/v at a flow rate of 0.7ml/min with column temperature maintained at 40°C and 10 μ l injection volume. The detection was carried out at 286nm by a UV-visible detector. The retention time of Venetoclax was found to be 4.19 minutes. The proposed method was linear over the range of 5-50 μ g/ml with a correlation coefficient (R²) of 0.9998. The limits of detection and quantification values were found to be 0.53 μ g/ml and 1.62 μ g/ml respectively. All validation parameters were within the limits as per the ICH guidelines. The results of validation parameters indicate that the developed HPLC method was specific, accurate, precise, rapid, reliable and reproducible, therefore it can be applied for routine quality control analysis of Venetoclax in its tablet dosage form.

Keywords: Venetoclax, RP-HPLC, ICH Guidelines, Validation, Method Development.

I. INTRODUCTION

Venetoclax is a medication used to treat adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and acute myeloid leukemia (AML). Venetoclax attaches to a protein called Bcl-2. This protein is present in high amounts in the CLL cancer cells, where it helps the cells survive for longer in the body and makes them resistant to cancer medicines. By attaching to Bcl-2 and blocking its actions, Venetoclax causes the death of cancer cells and thereby slows down the progression of disease. The chemical name of Venetoclax is 4-(4-{[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl}-1-piperazinyl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide (Figure 1). Its molecular formula is C₄₅H₅₀ClN₇O₇S having molecular weight 868.45 g/mol [1].




Figure 1 : Chemical Structure of Venetoclax

A. Literature Survey

Literature survey revealed only one UHPLC-MS/MS method for Venetoclax in rat plasma. No reliable or satisfactory RP-HPLC method was found for Venetoclax in pharmaceutical dosage forms. Hence attempts were made to develop a simple, rapid, precise, and accurate reverse phase chromatographic method to estimate Venetoclax in its tablet dosage form. The proposed method was optimized and validated as per ICH guidelines. The main objective is to give an overview of the mechanism of Reversed-Phase High Performance Liquid Chromatography and to explain the basis of the retention mechanism and achieve high-speed separation without loss of reproducibility.

II. INSTRUMENTATION WORK

A. Chemicals and Reagents

Venetoclax reference standard of defined potency 99.9% was procured from Central Drugs Testing Laboratory, Mumbai and Venclyxto (Venetoclax) 100mg film coated tablets manufactured by AbbVie Inc. were provided by Central Drugs Testing Laboratory, Mumbai. Acetonitrile (HPLC grade) from Merk Life science, methanol (HPLC grade) from Molychem, triethylamine from Rankem and orthophosphoric acid was from Avra. Ultra purified HPLC grade water was obtained from the Milli - Q® system (Millipore, Milford, MA, USA) water purification unit. The mobile phase was filtered using 0.45µ nylon filters by Axiva Sischem Pvt. Ltd. and was sonicated and degassed using a sonicator.

B. Instrumentation Work

Chromatographic research work was performed on Perkin Elmer HPLC System and Thermo Scientific Ultimate 3000 HPLC system equipped with a UV-visible detector. Data analysis and report generation were carried out using chameleon 7.4.2 software with LC instrument control. The wavelength of Venetoclax was determined on a Lab India UV visible spectrophotometer using UV Win software. Chromatographic separation was achieved on Perkin C8 (15cm x 4.6mm id, 5µ) column. For all weighing requirements a Sartorius Analytical Balance was used.

C. Determination of Wavelength

The standard solution 10 µg/ml of Venetoclax was scanned in the range of 400-200 nm against diluent as a blank. Venetoclax showed maximum absorbance at 286 nm as shown in Figure 2. So, the suitable wavelength selected for HPLC analysis was 286nm.




Figure 2 : UV Spectra of Venetoclax

D. Mobile Phase Preparation

Acetate Buffer (25 mM) and acetonitrile in a ratio of 55:45 v/v were used as a mobile phase for the present study. Two different ports were used for running of the mobile phase in isocratic form. Acetate buffer was prepared by dissolving 1.926 gm of Ammonium Acetate into 1000 ml HPLC grade water followed by adjusting pH to 3 with orthophosphoric acid. The mobile phase was sonicated for 10 minutes and degassed using an ultra sonicator. This preparation was then filtered by a 0.45µ mobile phase filter and thus used for the further chromatographic analysis.

E. Diluent Preparation

A mixture of acetonitrile and water in the ratio of 1:1 v/v was used for the preparation of the standard solutions and sample solutions of Venetoclax.

F. Preparation of Standard Solution

A standard stock solution of 100 µg/ml was prepared by accurately weighing 10.0 mg of Venetoclax and transferring it into a 100 ml volumetric flask. To this add 50.0 ml of diluent and dissolve the drug properly by sonicating for about 5 min, make up the solution to 100 ml with the diluent. Working standard solution of concentration 25 µg/ml of Venetoclax was obtained by pipetting out 5.0 ml of standard stock solution and transferring it into 20.0 ml volumetric flask and making up to the mark with the diluent.

G. Preparation of Sample Solution

About 5 film coated tablets of Venclyxto 100mg containing Venetoclax were weighed, and the average weight was calculated. The tablets were then crushed with the help of mortar pestle to create a fine powder that would dissolve quickly in the diluent. The powder equivalent to 100mg of drug was taken (around 1124.3 mg) and transferred into a 200ml volumetric flask making up to the mark with the diluent. This resulted in a 500 µg/ml sample stock solution. Final Sample solution of concentration 25 µg/ml of Venetoclax was obtained by pipetting out 5.0 ml of the above solution and transferring it into 100.0 ml volumetric flask and making up to the mark with the diluent.

H. Chromatographic Conditions

The mobile phase consisted of 25 mm (Approx 1.927gm) of Ammonium acetate adjusted to pH 3 with orthophosphoric acid and acetonitrile in the ratio of 55:45 v/v. The mobile phase was pumped through the column at a flow rate of 0.7 ml/min. Perkin C8 (15cm x 4.6mm id, 5µ) column was used for analysis at a column temperature maintained at 40⁰ C. The sample injection volume was 10 µl. The UV detector was set to 286 nm for detection and the chromatographic runtime was kept for 10 minutes.

III. METHOD OPTIMIZATION

Based on the chemical nature of Venetoclax, different mobile phase systems and HPLC columns were tried to obtain a proper separation of the molecule. The initial trials were carried out on Perkin Elmer HPLC system using Inertsill C18 (4.6 x 250mm x 5 µm) column with a mobile phase consisting of 25mm KH₂PO₄ and Acetonitrile in the ratio of 70:30 v/v with an injection volume of 10µL and flow rate of 1ml/min. However, Broad peak shape was observed, and the theoretical plates were not in the acceptable limits. So for this reason this particular trial was rejected.

Further trials were carried out on Zorbax eclipse C8 (4.6 x 150mm x 5µL) column using 0.1% trifluoroacetic acid and acetonitrile (50:50 v/v) as a mobile phase with a flow rate of 1ml/min and 10µL injection volume. However, poor peak shape was observed even after changing the column and varying the ratio of the mobile phase components. Thus, this specific trial was dismissed for this purpose.

Additional trials were carried out on Thermo Scientific Ultimate 3000 HPLC system on Perkin C8 (15cm x 4.6mm id, 5µ) column with a mobile phase consisting of 25 mm Ammonium acetate and Acetonitrile in the ratio of 70:30. With a flow rate of 0.8ml/min and 10µL injection volume. In this situation the peak was sharp but retention time of peak exceeded for about 10 minutes. For this reason the current trial was not taken into consideration.

The final trial was conducted by keeping all the conditions similar and slightly changing the mobile phase ratio of Acetate Buffer and Acetonitrile to 55:45. Including a flow rate of 0.7ml/min. Under these conditions, the peak was eluted with a good peak shape and acceptable system suitability parameters.

IV. METHOD VALIDATION

The developed RP-HPLC method was validated for system suitability testing, specificity, linearity, precision, accuracy and recovery, LOD, LOQ, and robustness as per ICH guidelines.

A. System Suitability Studies

System suitability is a set of pre-defined criteria that evaluate the performance of the HPLC system, encompassing factors such as resolution, peak symmetry, tailing factor, retention time, and peak area. This criteria is essential for consistent and precise analysis, as it confirms that the instrument is operating optimally and is capable of generating dependable data [2].

System suitability parameters were evaluated and analysed to check the system performance by injecting a working standard solution (six replicate) of concentration 25µg/ml and blank preparation (single injection) into the HPLC. The chromatograms were recorded to evaluate SST parameters like %RSD of Retention time, Tailing factor, Theoretical plates. Data of system suitability study is summarized in Table 1.

SYSTEM SUITABILITY STUDIES				
Sr No.	Peak Area	Retention Time	Theoretical Plates	Tailing Factor
1	14334.41	4.19	5109	0.770
2	14350.00	4.19	5105	0.770
3	14329.93	4.19	5129	0.770
4	14334.68	4.19	5065	0.770
5	14342.68	4.19	5109	0.770
6	14344.36	4.20	5160	0.770
Average	143396.34	4.1928	51128.33	0.770
Std Deviation	362565.28	0.0041258	31.19	0.00
%RSD	0.55	0.10	0.61	0.00
Limit	NMT 2.0 %	NMT 1.0%	NMT 2.0%	NMT 2.0%

Table No. 1 : System Suitability Data of Venetoclax.

B. Specificity

Specificity is the ability of the analytical method to distinguish between the analyte(s) and the other components in the sample matrix. In case of an HPLC method, it is assured by complete separation of peak(s) of analyte(s) from other peaks originated from the sample matrix. Specificity evaluation was done by injecting separately 25 µl solution of standard, sample, placebo, and blank into the chromatographic system. their chromatograms were recorded as represented in Figure 3,4,5 respectively [3].




Figure 3 : Chromatogram of Blank Solution




Figure 4 : Chromatogram of Standard Solution.




Figure 5 : Chromatogram of Sample Solution

C. Linearity

Linearity of a method is its ability to obtain test results that are directly proportional to the sample concentration over a given range. The capacity of an analytical process to produce test results that are directly proportional to the concentration of analyte in the sample (within a certain range) is referred to as linearity. If the method is linear, the test findings are proportional to the concentration of analyte in sample within a given range, either directly or through a well-defined mathematical transformation [4].

The linearity studies on Venetoclax were carried out in the concentration range of 5-50μg/mL and the correlation coefficient was found to be 0.9998. The regression equation obtained was found to be $y=996.73x+607.34$. The linearity graph was plotted by taking the concentration of the drug on the X-axis and the corresponding peak area on the Y-axis as shown in Fig 6.




Figure. 6 : Calibration Curve of Venetoclax

D. Limit of Detection and Limit of Quantitation

Sensitivity of the proposed method was estimated in terms of LOD and LOQ. Limit of detection is the lowest concentration in a sample that can be detected, but not necessarily quantified, under the stated experimental conditions. Limit of quantification is the lowest concentration of analyte in a sample that can be determined with acceptable precision [5].

The ICH indicates that LOD (which they call DL, the detection limit) can be calculated as $LOD = 3.3\sigma / S$, and the limit of quantification (which they call QL, the quantitation limit) $LOQ = 10\sigma / S$. Where 's' is the slope of the calibration curve and 'σ' is the standard deviation of the regression response. The values of the detection limit and quantification limit are calculated from calibration curve data. LOD and LOQ values are presented in Table No. 2.

Regression Statistics	
Linear Range	5–50µg/ml
Regression Equation	$y = 996.73x + 607.34$
Slope	996.73
Intercept	607.34
R^2	0.9998
Standard Deviation	106.36
LOD	0.53µg/ml
LOQ	1.62µg/ml

Table No.2 : Sensitivity Data of Venetoclax .

E. Precision

Precision is the agreement between replicate measurements of the same sample. The precision of analytical procedure expresses the closeness of agreement between series of measurements obtained from multiple sampling of the same homogenous samples under the prescribed conditions. It is expressed as relative standard deviations of replicate measurements [6].

1) System Precision

The system precision evaluates the reliability of the analytical system to precisely measure the component while the method precision takes into account also the variability of the sample preparation. This parameter was performed by injecting six replicate injections of a standard solution (25 µg/mL) . The mean, SD, and %RSD of peak areas of six replicate injections were calculated and studied as per the ICH guidelines acceptance criteria. The results are summarized in Table No. 3.

2) Method Precision (Assay Repeatability)

Six replicate injections of 25µg/ml of standard solution and six replicate injections of 25µg/ml of sample solution were injected into the HPLC system. The %assay, mean, S.D., and %RSD were calculated and studied as per the ICH guidelines acceptance criteria. The results are summarized in Table No. 3.

System Precision		Method Precision	
Sr. No.	Area	Sr. No.	Assay
1.	14334.40	1.	100.61
2.	14349.99	2.	100.57
3.	14339.93	3.	100.58
4.	14334.68	4.	100.14
5.	14342.68	5.	100.80
6.	14344.35	6.	100.06
Mean	14339.34	Mean	100.62
S.D.	7.541	S.D.	0.291
% RSD	0.053	% RSD	0.289
Limit	NMT 2%	Limit	NMT 2%

Table No. 3 : Precision Data of Venetoclax

3) Intra Day Precision

This was performed on day one at two different time intervals . Six replicate injections of 25µg/ml of standard solution and six replicate injections of 25µg/ml of sample solution were injected into the HPLC system. The assay, mean, S.D and %RSD were calculated and studied as per the ICH guidelines acceptance criteria. The data of Intra Day Precision summarised in Table. No.4.

Sr. No	% Assay (11:00 AM)	% Assay (3:00 PM)
1.	100.61	100.77
2.	100.57	100.67
3.	100.58	100.55
4.	100.14	100.72
5.	100.80	100.87
6.	101.01	100.66
Mean	100.62	100.71
S.D	0.290	0.109
% RSD	0.288	0.108
Limit	NMT 2%	NMT 2 %

Table No. 4 : Intra-Day Precision Data of Venetoclax

4) Intermediate Precision

This was performed on two different days and different HPLC instruments. Six replicates of standard solution (25µg/ml) and three sample preparation (25µg/ml) in triplicates were injected into the HPLC system. Its % Assay, average, SD, %RSD were calculated and reported. Results are summarized in Table No. 5.

Sr. No	% Assay Day 1	% Assay Day 2	% Assay Analyst 1	% Assay Analyst 2
1.	101.36	100.52	99.81	99.72
2.	100.95	99.57	99.67	99.58
3.	101.06	101.2	99.88	99.46
4.	101.33	98.51	99.68	99.71
5.	101.12	101.00	99.62	99.68
6.	101.33	100.06	99.79	99.75
Mean	101.19	100.08	99.64	99.73
S.D.	0.172	0.130	0.100	0.140
% RSD	0.170	0.998	0.100	0.120
Limit	NMT 2 %	NMT 2 %	NMT 2%	NMT 2%

Table No. 5 : Intermediate Precision Data of Venetoclax

F. Accuracy and Recovery

The accuracy of an analytical procedure expresses the closeness of the agreement between the value which is accepted either as a conventional true value or an accepted reference value and the value found. The accuracy of the method is the closeness of the measured value to the true value for the sample⁷.

Accuracy was determined with the help of standard addition method, by calculating of % mean recovery of the sample at Four different levels 100, 110, 120, 130%. At each level, three determinations were performed, the amount recovered, % recovery, and % RSD were taken into consideration. Accuracy results at various levels of concentration are summarized in Table No. 6

Level	Amount of Std Spiked (ml)	Amount Recovered (mg)	% Assay	% Recovery	Average	S.D.	% RSD	Mean % Recovery
100%	0	100.98	99.98	100.98	100.90	0.091	0.091	100.60 %
	0	100.82	99.80	100.8				
	0	100.91	99.91	100.91				
110%	0.5	110.84	100.84	100.76	101.28	0.051	0.051	
	0.5	111.94	111.94	101.76				
	0.5	112.46	113.46	101.33				
120%	1	121.36	121.36	101.13	100.41	0.068	0.068	
	1	119.72	125.72	99.77				
	1	120.48	128.42	100.33				
130%	1.5	129.46	130.46	99.58	100.50	0.079	0.079	
	1.5	131.46	131.46	101.12				
	1.5	130.73	130.73	100.56				

Table No. 6 : Accuracy Data of Venetoclax

G. Robustness

The robustness of an analytical procedure is a measure of its capacity to remain unaffected by small, but deliberate variations in method parameters and provides an indication of its reliability during the normal usage. Robustness testing was performed by a change in flow rate (± 0.2 ml/min), change in column temperature ($\pm 2^{\circ}\text{C}$), change in wavelength ($\pm 2\text{nm}$), Change in mobile phase (± 2). One sample of $25\mu\text{g/ml}$ was prepared and injected in triplicate along with five replicate injections of a standard solution of $25\mu\text{g/ml}$ under different chromatographic conditions. Its % assay, average, SD, %RSD were calculated and reported, results are summarized in Table. No.7.

Parameters	Change In Parameters	% Assay Estimation	Mean	S.D	% RSD	Limit
Flow Rate (± 0.2 ml/min)	0.5 ml	100.25	99.88	0.1517568	0.1517568	NMT 2 %
	0.7 ml	101.00				
	0.9 ml	99.81				
Column Temperature (± 0.2 ⁰ C)	38 ⁰ C	101.79	100.26	0.1753985	0.1754768	
	40 ⁰ C	101.55				
	42 ⁰ C	102.40				
Wavelength (± 2nm)	284nm	100.88	99.68	0.9875645	0.9874435	
	286 nm	101.25				
	288 nm	102.45				
Mobile Phase (± 2)	53:43	100.33	100.44	0.6435296	0.6438673	
	55:45	100.56				
	57:47	100.88				

Table No. 7 : Robustness Data of Venetoclax

H. Analysis of Formulation

The optimized method was applied on tablets having a label claim of Venetoclax 100 mg. The assay was performed on the above solution wherein five replicate injections of standard preparation $25\mu\text{g/ml}$ and six sample preparation of $25\mu\text{g/ml}$ in triplicate were injected into the HPLC system. Its % assay, average, SD, %RSD were calculated and reported, results are summarized in Table. 8

Sample No	Weight of Standard (mg)	Sample weight (equivalent to 100 mg of Venetoclax)	Mean Area of the standard at 286 nm	Area of sample at 286 nm	% Assay
1.	10.54	112.43	11845.42	15678.07	100.78
2.		112.55		16982.83	99.02
3.		112.64		19876.54	100.01
4.		112.78		11487.33	99.22
5.		112.84		17645.21	100.52
6.		112.43		14649.35	100.83
Mean					100.35
S.D.					0.4732
% RSD					0.3865

Table No. 8 : Assay results of Venetoclax

V. FORCED DEGRADATION STUDIES

Chromatograms of acidic and alkaline degradation showed extra peaks indicating mild degradation, i.e. 2.96 % degradation in acidic conditions and 11.56 % in basic conditions. Venetoclax was found to be stable to water hydrolytic, oxidative, thermal and photolytic stress conditions and hence no degradation was observed. Degradation products formed were well separated under-developed conditions. The peak purity of the main peak was found to be 100 %, as the peaks of degradation. Products were successfully separated from the main peak of Venetoclax without any interference. The acceptance limit of peak purity is not less than 99 %. This confirms the stability indicating nature of the proposed method. The data of forced degradation studies is summarized in Table No.9 .

Sr. No	Degradation	Conditions	Duration	Retention time of Degradation products (min)	% Residual Drug	Observed peak purity (%)
1.	Acid Degradation	1ml of 2N HCL at 60°C	1h	3.42	98.05	100.51
2.	Alkali Degradation	1 ml of 0.1N NaOH at 60°C	1h	4.13	88.33	100.42
3.	Oxidative Degradation	1ml of 3% H ₂ O ₂ at 60°C	1h	4.15	100.00	100.76
4.	Water Hydrolysis	1ml of Water at 60°C	1h	4.19	100.00	100.88
5.	Thermal Degradation	Hot water bath at 100°C	1h	4.11	100.00	100.93
6.	Photolytic Degradation	UV lamp (254nm)	24h	4.18	100.00	100.12

Table No. 9 : Forced Degradation Data of Venetoclax.

VI. RESULTS AND DISCUSSION

A simple, rapid, isocratic method was developed for determination of Venetoclax in pharmaceutical tablet dosage form. Optimization of method was done by the choice of mobile phase composition selection of column, selection of wavelength, injection volume, temperature, flow rate. The observed chromatogram of Venetoclax standard and sample solution gives sharp peak with retention time of 4.19 min. Linearity is observed over a concentration range of 5-50 µg/ml for Venetoclax. The correlation coefficient was found to be 0.9998. The relative standard deviation for system suitability testing and system precision studies were found to be less than 2%. Theoretical plates were found to be greater than 2000, also the tailing factor was reported to be less than 2. In Method precision (assay repeatability) studies of Venetoclax average assay percentage were found to be 100.35% which was within the limit i.e., between 98% to 102%. The relative standard deviation for all intermediate precision parameters was found to be within the limit. The accuracy studies were shown as % recovery at 100% to 130% level for Venetoclax. The mean percent recovery was found to be 100.60 % which was within the limit. Hence the method was found to be accurate. The present method can detect and quantify the analyte at a lower concentration. Limit of detection and limit of quantification values were estimated as following, LOD = 0.53 µg/ml, LOQ = 1.62 µg/ml where standard deviation (106.36) and slope (s = 996.73) values were obtained by the calibration curve method. By analyzing robustness, resultant values were found to be within a limit that is less than 2%, thus the developed method was confirmed to be robust. The results obtained from the assay show that the percentage recoveries were high, and SD values are very low, which confirms that the method is suitable for routine analysis of Venetoclax in its pharmaceutical preparation.

VII. CONCLUSION

The present RP-HPLC method was developed for quantitative and qualitative estimation of Venetoclax in its pharmaceutical tablet dosage form. The proposed method was successfully validated for parameters such as system suitability, linearity, accuracy, precision, robustness, LOD & LOQ and assay as per the ICH Q2(R2) guidelines. The results for all validation parameters were within the acceptable limits.

The developed RP-HPLC method was found to be simple, selective, precise and accurate. Also, this method uses lesser mobile phase, simple reagents with minimum preparations and shorter duration for analysis. The present RP-HPLC method can be used for routine analysis and quality control of Venetoclax in tablet dosage form in the pharmaceutical industry.

VIII. ACKNOWLEDGEMENT

This research work would not have been possible without the guidance and help of several individuals who in one way or another contributed and extended their valuable assistance in the preparation and completion of this work. I express my warmest gratitude to the Director of Central Drug Testing Laboratory, Mumbai for providing us with the opportunity to make the best use of their facility and resources. My sincere thanks to Dr. Vijay Kumar Munipalli (Head Analytical R and D Department, Central Drugs Testing Laboratory Mumbai) for being the guiding light throughout the tenure of the project. It gives me immense pleasure in expressing my sincere regards and gratitude to Dr. Smita Nayak (Professor, HOD., Pharmaceuticals, Gahlot Institute of Pharmacy, Navi Mumbai) who provided me this opportunity to work with such a prestigious organization. Last but not the least, I am extremely thankful to my instructors Mr. Shravan Kumar and Ms. Vasanti Mahamuni at CDTL Mumbai, for imbibing me with their valuable inputs and constant guidance.

REFERENCES

- [1] Rajendra A, Sengar M. Venetoclax: A narrative drug review. *Cancer Research, Statistics, and Treatment*. 2022 Jul 1;5(3):519-32.
- [2] Le TH, Phung TH, Le DC. Development and validation of an HPLC method for simultaneous assay of potassium guaiacolsulfonate and sodium benzoate in pediatric oral powder. *Journal of analytical methods in chemistry*. 2019;2019(1):6143061.
- [3] Sadapha P, Dhamak K. Review article on high-performance liquid chromatography (HPLC) method development and validation. *International Journal of Pharmaceutical Sciences Review and Research*. 2022;74(03):23-9.
- [4] Kalal DJ, Redasani VK. Stability-indicating RP-HPLC method development and validation for estimation of Mupirocin calcium in bulk and in pharmaceutical formulation. *Future Journal of Pharmaceutical Sciences*. 2022 Mar 28;8(1):21.
- [5] Ganji S, Dhulipala S, Nemala AR. Development and validation of RP HPLC method for the estimation of Sofosbuvir and related impurity in bulk and pharmaceutical dosage form. *Future journal of pharmaceutical sciences*. 2021 Dec;7:1-0. Sangeetha M, Reichal CR, Indulatha VN, Thirumoorthy N. Development and Validation of RP-HPLC Method: An Overview. *Research and Reviews: Journal of Pharmaceutical Analysis*. 2014;3(4):8-14.



10.22214/IJRASET



45.98



IMPACT FACTOR:
7.129



IMPACT FACTOR:
7.429



INTERNATIONAL JOURNAL FOR RESEARCH

IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY

Call : 08813907089  (24*7 Support on Whatsapp)